Every Form 4 that Enanta Pharmaceuticals, Inc (ENTA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ENTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTA filings page.
ENANTA PHARMACEUTICALS INC Chief Medical Officer Scott T. Rottinghaus reported a Code F transaction involving company common stock. On 2026-08-08, 1,467 shares of common stock were forfeited at a reference value of $13.34 per share to cover withholding taxes arising from the settlement of a portion of a restricted stock unit award originally granted on August 8, 2022. Following this tax-withholding disposition, Rottinghaus directly holds 23,787 shares of ENANTA common stock.
Enanta Pharmaceuticals director Terry Vance received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of 14.1700 per share and expire on March 11, 2036. Following this grant, Vance holds 20,000 options.
The option award vests monthly in substantially equal installments over one year starting on March 11, 2026, with the final monthly installment vesting no later than the nearest Nasdaq Global Select Market trading day before Enanta’s 2027 annual stockholders’ meeting. This is a compensation-related grant, not an open-market share purchase.
Enanta Pharmaceuticals director Lesley Russell received a stock option grant for 20,000 shares of Common Stock. The option has an exercise price of $14.17 per share and expires on March 11, 2036. It vests in substantially equal monthly installments over one year starting on March 11, 2026, with the final installment vesting before the 2027 annual meeting of stockholders.
ENANTA PHARMACEUTICALS director Kristine Peterson reported a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $14.17 per share, were granted on March 11, 2026, and expire on March 11, 2036. They vest in substantially equal monthly installments over one year starting from the grant date, reflecting a compensation-related award rather than an open-market trade.
Enanta Pharmaceuticals director Yujiro S. Hata received a grant of stock options for 20,000 shares of common stock. The options have a $14.17 exercise price, were granted on March 11, 2026, and expire on March 11, 2036.
The options will vest in substantially equal monthly installments over one year starting from the March 11, 2026 grant date, with the final monthly installment vesting no later than the nearest Nasdaq Global Select Market trading day before the 2027 annual stockholders meeting. Following this grant, Hata holds 20,000 stock options directly.
Enanta Pharmaceuticals director Mark G. Foletta received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $14.17 per share, were granted at no cost, and expire on March 11, 2036.
The award vests monthly in substantially equal installments over one year, beginning on March 11, 2026, with the final installment vesting no later than the trading day before the 2027 annual stockholder meeting. Following this grant, Foletta holds options for 20,000 shares directly, reflecting routine equity-based director compensation rather than an open-market purchase or sale.
Enanta Pharmaceuticals director Bruce L. A. Carter received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $14.17 per share and expire on March 11, 2036. They become exercisable monthly in substantially equal installments over one year starting March 11, 2026, with final vesting no later than the trading day before the 2027 annual stockholders meeting. Following this grant, he holds options on 20,000 shares directly.
Enanta Pharmaceuticals’ Chief Legal Officer Matthew Paul Kowalsky reported equity compensation activity in company stock. On February 12, 2026, he acquired 1,318 shares of common stock from performance share units that vested based on 2024-2025 research and development milestones. He also acquired 4,175 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index. To cover withholding taxes from these vestings, 1,902 shares were automatically disposed of at $14.25 per share, leaving him with 3,591 shares of Enanta common stock held directly after the transactions.
Enanta Pharmaceuticals’ Chief Business Officer Brendan Luu reported equity compensation activity. On February 12, 2026, he acquired 1,575 shares of common stock through performance share units tied to 2024–2025 research and development milestones, and 4,987 shares through a relative total stockholder return unit award, both at $0 per share.
On the same date, 3,257 shares were automatically forfeited at $14.25 per share to cover withholding taxes arising from settlement of these awards. After these transactions, Luu directly beneficially owned 41,634 shares of Enanta common stock.
Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported equity compensation transactions in Enanta common stock. On February 12, 2026, she acquired 1,575 shares through performance share units that vested based on 2024-2025 research and development milestones, as determined by the Compensation Committee. She also acquired 4,987 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index over matching 60-day periods two years apart. To cover withholding taxes from these awards, 3,257 shares were automatically forfeited at a price of $14.25 per share. Following these transactions, she directly held 33,925 shares of Enanta common stock.
Enanta Pharmaceuticals Chief Medical Officer Scott T. Rottinghaus reported equity award activity in company stock. On February 12, 2026, he acquired 1,650 shares of common stock at $0 per share from performance share units that vested based on research and development milestones for the 2024-2025 period.
On the same date, he acquired an additional 5,225 shares at $0 per share from a relative total stockholder return unit award tied to Enanta’s performance versus the Nasdaq Biotech Index. Also on February 12, 2026, 3,413 shares were disposed of at $14.25 per share to satisfy withholding taxes related to settlement of these awards. After these transactions, he directly owned 25,254 shares of Enanta common stock.
Enanta Pharmaceuticals’ Chief Scientific Officer Or Yat Sun reported equity compensation activity. On February 12, 2026, Sun acquired 1,650 shares of common stock from performance share units tied to 2024–2025 R&D milestones and 5,225 shares from a relative total stockholder return unit award, both at $0 per share. On the same date, 3,413 shares were automatically forfeited at $14.25 per share to cover withholding taxes from settlement of these awards. Following these transactions, Sun directly owned 374,854 common shares.
Enanta Pharmaceuticals President and CEO Jay R. Luly, who is also a director, reported equity award activity in Enanta common stock. On February 12, 2026, he acquired 4,800 shares through performance share units tied to 2024-2025 R&D milestones and 15,200 shares from a relative total stockholder return unit award, both at no cash price. On the same date, 6,155 shares were automatically withheld and forfeited at $14.25 per share to cover tax obligations from these vestings. After these transactions, he directly beneficially owned 871,871 shares of Enanta common stock.
Enanta Pharmaceuticals’ chief business officer reported a small share withholding related to previously granted equity. On 12/01/2025, 498 shares of Enanta common stock were forfeited at $14.12 per share to cover withholding taxes from the settlement of a portion of a restricted stock unit award granted on November 19, 2021.
After this tax-related share forfeiture, the officer beneficially owns 39,723 shares of Enanta common stock in direct ownership. The transaction reflects routine equity compensation and tax settlement activity for a senior executive.
Enanta Pharmaceuticals (ENTA) reported an equity compensation grant to its Vice President, Finance, who is its principal financial officer. On 11/25/2025, the officer received 6,463 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing direct beneficial ownership of common stock to 17,375 shares following the transaction. The RSUs vest 25% on December 1, 2026, then in substantially equal annual installments over the next three anniversaries.
The filing also reports a grant of a stock option for 12,925 shares of common stock at an exercise price of $13.66 per share, expiring on 11/25/2035. This option becomes exercisable in substantially equal quarterly installments over four years from the grant date of November 25, 2025, resulting in 12,925 derivative securities beneficially owned after the transaction, all held directly.
Enanta Pharmaceuticals (ENTA) reported a new equity award to an executive officer. The filing shows the Chief Product Strategy Officer received a stock option to buy 100,000 shares of Enanta common stock at an exercise price of $13.66 per share, granted on November 25, 2025.
The option becomes exercisable in substantially equal quarterly installments over four years from the grant date, with any fractional shares carried forward to the next period, and expires on November 25, 2035. Following this grant, the reporting person beneficially owns 100,000 derivative securities directly in the form of this stock option.
Enanta Pharmaceuticals Inc. (ENTA) reported a stock option grant to its Chief Scientific Officer on a Form 4. On November 25, 2025, the officer received a stock option to purchase 110,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.
The option covers 110,000 underlying shares of common stock and is held directly. It becomes exercisable, subject to continued employment, in substantially equal quarterly installments over four years from the grant date, with fractional shares cumulated and becoming exercisable once a whole share equivalent is reached.
Enanta Pharmaceuticals Inc. (ENTA) reported a new equity award to its President and CEO, who also serves as a director. On November 25, 2025, the insider received a stock option to purchase 310,000 shares of Enanta common stock at an exercise price of $13.66 per share, expiring on November 25, 2035.
The option is scheduled to become exercisable in substantially equal quarterly installments over four years from the grant date, subject to the optionholder’s continued employment. Following this grant, the reporting person beneficially owns 310,000 derivative securities directly in the form of this stock option.